If you've spent any time in the wellness or biohacking space, you've encountered MTHFR. It's the gene that launched a thousand supplement recommendations, a thousand blog posts about methylation, and a thousand confused conversations with doctors who aren't sure what to do with the information.
Some of the claims circulating about MTHFR are real. Many are exaggerated. A few are outright wrong. Here's a science-first breakdown of what your MTHFR status actually means, what it doesn't mean, and what to do about it.
What MTHFR Actually Does
MTHFR stands for methylenetetrahydrofolate reductase. It's an enzyme that converts a form of folate (vitamin B9) called 5,10-methylenetetrahydrofolate into its active form, 5-methyltetrahydrofolate (5-MTHF). This active folate is essential for a biochemical process called methylation — the addition of a methyl group (CH₃) to other molecules.
Methylation is involved in DNA synthesis and repair, neurotransmitter production (serotonin, dopamine, norepinephrine), homocysteine metabolism, gene expression regulation, and detoxification pathways. It's a fundamental cellular process, not a fringe concept — which is why MTHFR variants get so much attention.
When the MTHFR enzyme works at reduced capacity due to genetic variants, the conversion of folate to its active form is impaired. This can lead to elevated homocysteine levels (since homocysteine recycling requires 5-MTHF) and potentially reduced methylation capacity in cells that depend on folate-derived methyl groups.
The Two Key Variants
C677T (rs1801133)
The most clinically studied MTHFR variant. The "T" allele reduces enzyme activity compared to the "C" (normal) allele. The effect depends on whether you carry one copy (heterozygous, CT) or two copies (homozygous, TT).
Heterozygous carriers (CT) have roughly 65% of normal enzyme activity — a modest reduction that, for most people, has minimal clinical impact. Homozygous carriers (TT) have approximately 30% of normal enzyme activity — a more significant reduction that can measurably affect folate metabolism and homocysteine levels.
The T allele is common. Depending on ethnicity, 10–15% of the population is homozygous TT, and 40–50% is heterozygous CT. This is not a rare mutation — it's a common population variant with variable health impact depending on diet, folate intake, and other genetic factors.
A1298C (rs1801131)
The second most studied variant. The "C" allele also reduces enzyme activity, but to a lesser degree than C677T. Homozygous CC carriers (A1298C) have approximately 60% of normal activity. The clinical impact of A1298C alone is generally considered minimal.
The combination that gets the most attention is compound heterozygosity — carrying one copy of the C677T variant AND one copy of the A1298C variant simultaneously. This combination reduces enzyme activity to roughly 50–60% of normal and is associated with moderately elevated homocysteine in some studies, though the clinical significance is debated.
What the Evidence Supports
Elevated homocysteine risk. The most well-established clinical consequence of MTHFR variants (particularly C677T TT) is elevated blood homocysteine. High homocysteine is an independent risk factor for cardiovascular disease, stroke, and venous thromboembolism. However, the relationship between MTHFR variants, homocysteine, and actual cardiovascular events is more nuanced than many wellness sources suggest — homocysteine is a risk marker, but lowering it with supplements hasn't consistently reduced cardiovascular events in clinical trials.
Neural tube defect risk. Women who are C677T TT homozygous have a modestly elevated risk of having a child with a neural tube defect (like spina bifida), particularly if their folate intake is insufficient. This is the most clinically actionable finding and one reason why folate supplementation is universally recommended during pregnancy — it's protective regardless of MTHFR status.
Folate metabolism. TT homozygous individuals process synthetic folic acid (the form found in fortified foods and most supplements) less efficiently than people with normal MTHFR function. Methylfolate (5-MTHF, the already-activated form) bypasses the MTHFR enzyme entirely, which is why it's often recommended for TT carriers.
What the Evidence Does NOT Support
MTHFR variants do not "cause" depression. While folate is involved in neurotransmitter synthesis, the relationship between MTHFR status and clinical depression is weak and inconsistent across studies. Many TT homozygous people have perfectly normal mental health. Many people with depression have perfectly normal MTHFR function.
MTHFR variants are not a diagnosis. Some wellness practitioners treat MTHFR status as a standalone condition requiring aggressive supplementation protocols. Major medical organizations, including the American College of Medical Genetics, do not recommend routine MTHFR testing for most clinical purposes. The variants are common population polymorphisms, not rare pathogenic mutations.
Detox protocols are not evidence-based. Claims that MTHFR variants impair "detoxification" and require specific supplement stacks (glutathione, SAMe, B12, methylfolate, TMG, NAC) in precise combinations are not supported by rigorous clinical evidence. Some of these supplements may be reasonable for specific individuals based on bloodwork, but the elaborate protocols marketed to MTHFR carriers are largely products of the supplement industry, not clinical science.
What to Actually Do If You're TT Homozygous
Get your homocysteine checked. A simple blood test. If it's elevated (above 15 µmol/L), there's a clear intervention pathway. If it's normal, your MTHFR variant isn't causing a clinical problem regardless of your genotype.
Consider methylfolate over folic acid. If you take a folate supplement or prenatal vitamin, choosing one with methylfolate (5-MTHF) rather than synthetic folic acid is a reasonable step. The cost difference is minimal and the logic is sound — you're providing the already-activated form that doesn't require MTHFR processing.
Eat folate-rich foods. Leafy greens, legumes, citrus, and liver are rich in natural food folate. Dietary folate doesn't require the same enzymatic processing as synthetic folic acid and is generally well-utilized regardless of MTHFR status.
Don't panic. Roughly 10–15% of the entire human population is C677T TT homozygous. Most of them are completely fine. MTHFR variants are extremely common and, for the vast majority of carriers, do not cause significant health problems — especially with adequate folate intake.
How Genome Testing Detects MTHFR
Both genotyping tests (23andMe, AncestryDNA) and whole genome sequencing (Dante Labs, Sequencing.com) detect the two main MTHFR variants. This is one area where genotyping and WGS provide equivalent results — the two variants are well-characterized, common, and included on standard genotyping arrays.
Where WGS adds value is in the broader methylation pathway context. MTHFR doesn't operate in isolation — it interacts with MTRR, MTR, COMT, CBS, BHMT, and other genes in the folate/methylation cycle. WGS captures the complete sequence of all these genes, enabling a more holistic assessment of your methylation pathway capacity rather than fixating on a single gene.
Tools like SelfDecode, Promethease, and FoundMyFitness all report MTHFR status and provide context on related pathway genes. If methylation is a topic you care about, uploading your WGS data to one of these platforms provides a more complete picture than your MTHFR status alone.
Full Methylation Pathway Coverage
Dante Labs WGS captures MTHFR, COMT, MTRR, MTR, CBS, and every other gene in your methylation cycle — not just two SNPs.
Get 10% Off with Code GENOME → Complete genome · 200+ reports · From €169 on flash sale